C07D 215/48
Carbon atoms having three bonds to hetero atoms with at the most
Official title: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D215/48 (Carbon atoms having three bonds to hetero atoms with at the most) appears on 2,078 US grants and 1,753 published applications in this corpus.
Search patents in C07D- Granted patents
- 2,078
- Published applications
- 1,753
- Assignees
- 870
- Inventors
- 6,092
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 12 | 0 |
| 1977 | 18 | 0 |
| 1978 | 12 | 0 |
| 1979 | 16 | 0 |
| 1980 | 12 | 0 |
| 1981 | 18 | 0 |
| 1982 | 11 | 0 |
| 1983 | 17 | 0 |
| 1984 | 24 | 0 |
| 1985 | 29 | 0 |
| 1986 | 22 | 0 |
| 1987 | 32 | 0 |
| 1988 | 45 | 0 |
| 1989 | 44 | 0 |
| 1990 | 56 | 0 |
| 1991 | 52 | 0 |
| 1992 | 43 | 0 |
| 1993 | 58 | 0 |
| 1994 | 43 | 0 |
| 1995 | 48 | 0 |
| 1996 | 46 | 0 |
| 1997 | 55 | 0 |
| 1998 | 61 | 0 |
| 1999 | 32 | 0 |
| 2000 | 39 | 0 |
| 2001 | 50 | 5 |
| 2002 | 59 | 52 |
| 2003 | 51 | 65 |
| 2004 | 51 | 103 |
| 2005 | 27 | 102 |
| 2006 | 56 | 94 |
| 2007 | 45 | 89 |
| 2008 | 52 | 74 |
| 2009 | 52 | 78 |
| 2010 | 40 | 88 |
| 2011 | 53 | 63 |
| 2012 | 50 | 73 |
| 2013 | 62 | 77 |
| 2014 | 69 | 94 |
| 2015 | 76 | 81 |
| 2016 | 53 | 69 |
| 2017 | 49 | 55 |
| 2018 | 37 | 56 |
| 2019 | 52 | 51 |
| 2020 | 41 | 71 |
| 2021 | 53 | 57 |
| 2022 | 40 | 62 |
| 2023 | 28 | 63 |
| 2024 | 33 | 55 |
| 2025 | 37 | 42 |
| 2026 | 17 | 34 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and compositions for treating cancer22 Sep 2026US 12,740,976 B2City of Hope
- Tautomeric ligand enables biomimetic C—H hydroxylation with molecular oxygen22 Sep 2026US 12,741,937 B2The Scripps Research Institute
- Compositions and methods for treating muscular dystrophies22 Sep 2026US 12,741,939 B2The Regents of the University of California
- Crystal form of quinolinone compound and use thereof25 Aug 2026US 12,715,846 B2Sunshine Lake Pharma Co., Ltd.
- Crystalline forms and salt forms of a kinase inhibitor14 Jul 2026US 12,679,809 B2Exelixis, Inc.
- Antidegradant bis(dihydro and tetrahydroquinoline) compounds and uses thereof8 Oct 2026US 2026/0308127 A1Flexsys IP Holdings, LLC
- Hydroxylamine-based bcr-abl1 inhibitors for treatment of cancer1 Oct 2026US 2026/0297031 A1University of Georgia Research Foundation, Inc.
- Quinolineimine antidegradant compounds and uses thereof24 Sep 2026US 2026/0285812 A1Flexsys IP Holdings, LLC
- Therapeutic compounds24 Sep 2026US 2026/0285836 A1Rutgers, The State University of New Jersey
- 3-(sulphonyl or sulfonimidoyl)prop-2-en-1-yl]-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives27 Aug 2026US 2026/0250250 A1
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Substituted 3-cyano quinolines164US 6,002,008 AAmerican Cyanamid Company · 1999